Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim is directly supported by the provided label excerpts: the boxed warning and Warnings (5.1) establish increased suicidal thoughts/behaviors risk in pediatric/young adult patients with required monitoring and caregiver counseling, and Pediatric Use (8.4) supports the pediatric scope.
Category Scores
Accurate Statements
Antidepressants (including TRINTELLIX) have an increased risk of suicidal thoughts and behaviors in pediatric and young adult patients (boxed warning; applies to pediatric and young adult patients).
Boxed Warning; 5.1 (increased incidence in patients age 24 years and younger); 8.4 (pediatric safety/effectiveness not established and reiterates increased risk).
Closely monitor patients and provide monitoring/counseling instructions; counsel family members/caregivers to monitor and alert the healthcare provider.
Boxed Warning; 5.1 (monitoring and caregiver counseling instructions); 17 (patient/caregiver counseling to watch for suicidal ideation/behavior).
Consider changing the therapeutic regimen (including possibly discontinuing TRINTELLIX) if suicidal thoughts and behaviors emerge.
5.1 (suggests considering changing the therapeutic regimen, including possibly discontinuing TRINTELLIX, in patients with emergent suicidal thoughts/behaviors).
Unsupported Statements
Contradictions
Important Omissions
The AI response/claim does not explicitly mention the specific age threshold used in the label analyses ("age 24 years and younger") or the uncertainty regarding longer-term use (beyond four months) stated in 5.1.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim reinforces label-consistent risk communication and monitoring/counseling requirements for suicidal thoughts/behaviors in pediatric/young adult populations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Could be more specific to the label wording (e.g., explicitly referencing the label's “age 24 years and younger” framing and/or the longer-term uncertainty statement in 5.1).
Suggested Improvement
When stating the scope of risk, mirror label phrasing from Boxed Warning/5.1 (e.g., “pediatric and young adult patients,” including “24 years and younger”) and, if relevant, mention the label’s statement about unknown extension to longer-term use.